Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease.Proceedings of the National Academy of Sciences.  115:E2634-E2643. 2018
2018 Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents.Journal of Parkinson's Disease.  8:303-322. 2018
2017 LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model.Molecular Therapy : Nucleic Acids.  8:508-519. 2017
2017 Effects of α-synuclein on axonal transport.Neurobiology of Disease.  105:321-327. 2017
2017 α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration.Neurobiology of Disease.  105:84-98. 2017
2016 G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.Journal of Neuroscience.  36:7415-7427. 2016
2016 How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?Journal of Neurochemistry.  139 Suppl 1:131-155. 2016
2016 microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease.Journal of Neuroscience.  36:2383-2390. 2016
2016 Invisible Killers.Movement Disorders.  31:44. 2016
2015 Trophic factors for Parkinson's disease: To live or let die.Movement Disorders.  30:1715-1724. 2015
2015 Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.Journal of Biological Chemistry.  290:19433-19444. 2015
2014 Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes.Cell regulation.  25:4010-4023. 2014
2014 Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.Journal of Biological Chemistry.  289:32937-32951. 2014
2014 Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates.Nature Protocols.  9:2135-2146. 2014
2014 Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.Journal of Comparative Neurology.  522:2465-2480. 2014
2014 Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats.Proceedings of the National Academy of Sciences.  111:9289-9294. 2014
2013 Calcium entry and α-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons.Journal of Neuroscience.  33:10154-10164. 2013
2013 Lewy body-like α-synuclein aggregates resist degradation and impair macroautophagy.Journal of Biological Chemistry.  288:15194-15210. 2013
2011 Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death.Neuron.  72:57-71. 2011
2010 Phosphatidylinositol-4-phosphate 5-kinases and phosphatidylinositol 4,5-bisphosphate synthesis in the brain.Journal of Biological Chemistry.  285:28708-28714. 2010
2005 Isoform-selective effects of the depletion of ADP-ribosylation factors 1-5 on membrane traffic.Cell regulation.  16:4495-4508. 2005
2004 Immunohistochemical localization of proteins in the nervous system.Current protocols in neuroscience / editorial board, Jacqueline N. Crawley ... [et al.].  Chapter 1:Unit-1.2. 2004
2003 Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice.Molecular Pharmacology.  64:1309-1316. 2003
2003 Altered hippocampal muscarinic receptors in acetylcholinesterase-deficient mice.Annals of Neurology.  53:788-796. 2003
2003 Regulation of muscarinic acetylcholine receptor function in acetylcholinesterase knockout mice.Pharmacology Biochemistry and Behavior.  74:977-986. 2003

Investigator On

  • Innate and Adaptive Immunity in Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • The Nigral Molecular Clock and Vulnerability to Neurodegeneration  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Contribution of the Interaction Between Synuclein and Tau in the Pathophysiology of Dementia with Lewy Bodies  awarded by National Institute on Aging/NIH/DHHS 2018 - 2022
  • Lysosomal Enhancement Strategies in Dopaminergic Neurodegeneration  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2019
  • Alpha-Galactosidase A: A Novel Target for Reducing Alpha-Synuclein Toxicity  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2019
  • Mechanisms of LRRK2 Mediated Neurotoxicity  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2019
  • Efficacies and Pharmacodynamic Assays for LRRK2 Small-Molecule Inhibitors  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018
  • Innate and Adaptive Immunity in Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2018
  • Innate and Adaptive Immunity in Parkinson Disease - Project 1: PD-Linked Susceptibilities in Myeloid-Cell CNS Infiltration  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2018
  • Identification of Robust and Relevant Pre-Clinical Phenotypes for LRRK2 Therapeutics  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2015 - 2018
  • Efficacies and Pharmacodynamic Assays for LRRK2 Small-Molecule Inhibitors  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2017
  • Validation of CCR2-Dependent Monocyte Entry in Alpha-Synuclein-Induced Toxicity  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2016 - 2017
  • Education And Training

  • Bachelor of Science or Mathematics, Franklin & Marshall College
  • Doctor of Philosophy in Neuroscience, Emory University
  • Full Name

  • Laura Volpicelli-Daley